SI1635838T1 - Zaviralci fosfodiesteraze tipa 5 za profilakso in/ali terapijo pri portalni hipertenziji - Google Patents
Zaviralci fosfodiesteraze tipa 5 za profilakso in/ali terapijo pri portalni hipertenzijiInfo
- Publication number
- SI1635838T1 SI1635838T1 SI200430378T SI200430378T SI1635838T1 SI 1635838 T1 SI1635838 T1 SI 1635838T1 SI 200430378 T SI200430378 T SI 200430378T SI 200430378 T SI200430378 T SI 200430378T SI 1635838 T1 SI1635838 T1 SI 1635838T1
- Authority
- SI
- Slovenia
- Prior art keywords
- portal hypertension
- portal
- inhibitor
- prevent
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10325813A DE10325813B4 (de) | 2003-06-06 | 2003-06-06 | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
PCT/EP2004/006014 WO2004108062A2 (de) | 2003-06-06 | 2004-06-03 | Prophylaxe und/oder therapie bei der portalen hypertonie |
EP04739573A EP1635838B1 (de) | 2003-06-06 | 2004-06-03 | Phosphodiesterase-5-inhibitoren zur prophylaxe und/oder therapie der portalen hypertonie |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1635838T1 true SI1635838T1 (sl) | 2007-10-31 |
Family
ID=33494881
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200431750T SI1923073T1 (sl) | 2003-06-06 | 2004-06-03 | Kombinirano zdravilo ki vsebuje pde-5 inhibitor |
SI200430378T SI1635838T1 (sl) | 2003-06-06 | 2004-06-03 | Zaviralci fosfodiesteraze tipa 5 za profilakso in/ali terapijo pri portalni hipertenziji |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200431750T SI1923073T1 (sl) | 2003-06-06 | 2004-06-03 | Kombinirano zdravilo ki vsebuje pde-5 inhibitor |
Country Status (14)
Country | Link |
---|---|
US (1) | US9278097B2 (sl) |
EP (2) | EP1923073B1 (sl) |
JP (3) | JP4557970B2 (sl) |
KR (2) | KR101233828B1 (sl) |
CN (1) | CN1871010B (sl) |
AT (2) | ATE525074T1 (sl) |
CY (2) | CY1107707T1 (sl) |
DE (2) | DE10325813B4 (sl) |
DK (2) | DK1635838T3 (sl) |
ES (2) | ES2287740T3 (sl) |
PL (2) | PL1923073T3 (sl) |
PT (2) | PT1635838E (sl) |
SI (2) | SI1923073T1 (sl) |
WO (1) | WO2004108062A2 (sl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1392314B1 (de) * | 2001-05-09 | 2006-12-20 | Bayer HealthCare AG | NEUE VERWENDUNG VON 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on |
DE10232113A1 (de) * | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
DE102005009240A1 (de) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
DK1888074T3 (da) * | 2005-06-10 | 2012-01-23 | Dong A Pharm Co Ltd | Middel til forebyggelsen og behandling af leversygdomme indeholdende pyrazolopyrimidinderivat |
US20090186896A1 (en) * | 2005-09-29 | 2009-07-23 | Bayer Healthcare Ag | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders |
US8512258B2 (en) * | 2005-11-11 | 2013-08-20 | Exalenz Bioscience Ltd. | Breath test device and method |
JP2010532319A (ja) * | 2007-06-13 | 2010-10-07 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 聴覚障害の処置用のpde阻害剤 |
WO2014088326A1 (ko) | 2012-12-04 | 2014-06-12 | 주식회사 아리바이오 | 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물 |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
WO2019006248A1 (en) | 2017-06-30 | 2019-01-03 | Georgia State University Research Foundation, Inc. | NON-INVASIVE METHODS FOR DETECTION OF HEPATIC FIBROSIS |
CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
CN110811593A (zh) * | 2019-11-07 | 2020-02-21 | 天津中医药大学第二附属医院 | 一种高血压中医证型采取肝血流动力学特点的判别方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2882843B2 (ja) * | 1990-03-28 | 1999-04-12 | 日本化薬株式会社 | 門脈圧亢進症改善剤 |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US5973011A (en) * | 1994-03-30 | 1999-10-26 | Isis Pharma Gmbh | Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction |
CZ20012627A3 (cs) | 1999-01-20 | 2002-01-16 | Arzneimittelwerk Dresden Gmbh | Pouľití imidazo [1,5-a] pyrido [3,2-e]pyrazinonů jako léčiva |
DE19961302A1 (de) * | 1999-12-18 | 2001-06-21 | Dresden Arzneimittel | Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen |
AU3210500A (en) * | 1999-01-22 | 2000-08-07 | Selectus Pharmaceuticals, Inc. | Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US20010003120A1 (en) * | 1999-05-14 | 2001-06-07 | M. D. Robert Hines | Method for treating erectile dysfunction |
FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
TWI224966B (en) | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
US20020103117A1 (en) | 2000-02-03 | 2002-08-01 | Ralph Knoell | Use of protein kinase-inhibitor-alpha |
DE10004858A1 (de) * | 2000-02-03 | 2001-08-16 | Schering Ag | Verwendung von Proteinkinase-Inhibitor-alpha |
US6476037B1 (en) | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
EP1313478A2 (en) | 2000-08-30 | 2003-05-28 | Lilly Icos LLC | Method for treatment of migraine using pde5 inhibitors |
US20020028764A1 (en) * | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
EP1329218A4 (en) | 2000-10-25 | 2007-04-04 | Takeda Pharmaceutical | AGENTS FOR PREVENTIVE AND TREATING PORTAL HYPERTENSION |
JP2002201128A (ja) * | 2000-10-25 | 2002-07-16 | Takeda Chem Ind Ltd | 門脈圧亢進症予防・治療剤 |
CN1499969A (zh) | 2001-01-31 | 2004-05-26 | Ĭ��ר���ɷ�����˾ | 含有吡唑并[4,3-d]嘧啶和硝酸酯或噻吩并嘧啶和硝酸酯的药物组合物 |
HUP0303005A3 (en) | 2001-02-02 | 2005-05-30 | Merck Patent Gmbh | Pharmaceutical compositions comprising pyrazolo[4,3-d]pyrimidines or thienopyrimidines and endothelin receptor antagonists |
AU2002226633A1 (en) * | 2001-02-02 | 2002-08-12 | Pfizer Limited | Treatment of diabetes mellitus using vardenafil |
US6338862B1 (en) * | 2001-03-26 | 2002-01-15 | Sarfaraz K Niazi | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
US7579435B2 (en) * | 2001-06-08 | 2009-08-25 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Somatostatin-dopamine chimeric analogs |
LV12979B (en) * | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
-
2003
- 2003-06-06 DE DE10325813A patent/DE10325813B4/de not_active Expired - Fee Related
-
2004
- 2004-06-03 PL PL06025229T patent/PL1923073T3/pl unknown
- 2004-06-03 WO PCT/EP2004/006014 patent/WO2004108062A2/de active IP Right Grant
- 2004-06-03 JP JP2006508268A patent/JP4557970B2/ja not_active Expired - Fee Related
- 2004-06-03 DE DE502004003694T patent/DE502004003694D1/de not_active Expired - Lifetime
- 2004-06-03 DK DK04739573T patent/DK1635838T3/da active
- 2004-06-03 DK DK06025229.3T patent/DK1923073T3/da active
- 2004-06-03 AT AT06025229T patent/ATE525074T1/de active
- 2004-06-03 SI SI200431750T patent/SI1923073T1/sl unknown
- 2004-06-03 ES ES04739573T patent/ES2287740T3/es not_active Expired - Lifetime
- 2004-06-03 EP EP06025229A patent/EP1923073B1/de not_active Expired - Lifetime
- 2004-06-03 SI SI200430378T patent/SI1635838T1/sl unknown
- 2004-06-03 US US10/559,694 patent/US9278097B2/en not_active Expired - Fee Related
- 2004-06-03 ES ES06025229T patent/ES2374085T3/es not_active Expired - Lifetime
- 2004-06-03 EP EP04739573A patent/EP1635838B1/de not_active Expired - Lifetime
- 2004-06-03 PT PT04739573T patent/PT1635838E/pt unknown
- 2004-06-03 PT PT06025229T patent/PT1923073E/pt unknown
- 2004-06-03 AT AT04739573T patent/ATE361074T1/de active
- 2004-06-03 CN CN2004800225122A patent/CN1871010B/zh not_active Expired - Fee Related
- 2004-06-03 KR KR1020117030506A patent/KR101233828B1/ko not_active IP Right Cessation
- 2004-06-03 PL PL04739573T patent/PL1635838T3/pl unknown
-
2005
- 2005-12-05 KR KR1020057023300A patent/KR101176110B1/ko not_active IP Right Cessation
-
2007
- 2007-08-01 CY CY20071101024T patent/CY1107707T1/el unknown
-
2009
- 2009-07-24 JP JP2009172766A patent/JP5757677B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-12 JP JP2010109855A patent/JP5631053B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-07 CY CY20111100960T patent/CY1111918T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107707T1 (el) | Αναστολεις της φωσφοδιεστερασης-5 για την προφυλαξη και/ή τη θεραπεια της πυλαιας υπερτασης | |
BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
NO20010844L (no) | Regulering av substrataktivitet | |
NO20033617L (no) | Fremgangsmate for behandling av diabetes mellitus | |
IL160420A0 (en) | Treating or preventing diabetes with cannabidiol | |
EP1500403A4 (en) | MEANS FOR THE PREVENTION / TREATMENT OF DIABETES | |
BR0315630A (pt) | Administração de combinação de uma indolinona com um agente quimioterapêutico para distúrbios de proliferação celular | |
TR200000129T2 (tr) | Yepyeni spiroazabisiklik heterosiklik bileşikler. | |
NZ510920A (en) | Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans | |
DE60116642D1 (de) | Verbindungen mit cytochrom p450ra1 hemmenden aktivität | |
MXPA04003547A (es) | Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido. | |
WO2007117981A3 (en) | Selective hydroxamate based mmp inhibitors | |
NO980221L (no) | Fremgangsmåte for behandling av tykktarmsadenomer | |
MXPA05012320A (es) | Tratamientos de trastornos bipolares y sintomas asociados. | |
EP1438063A4 (en) | MODULATION OF PHYSIOLOGICAL PROCESSES AND USEFUL MEANS | |
NO20051390L (no) | Fremgangsmate for behandling av pasienter med massivt blodtap | |
NZ519722A (en) | Treatment of diabetic ulcers | |
GEP20063822B (en) | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders | |
EP1447090B8 (de) | Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen | |
HUP0001097A2 (hu) | COMT-inhibitorok alkalmazása cukorbetegséggel kapcsolatos érrendszeri rendellenességek megelőzésére alkalmas gyógyszerkészítmények előállítására | |
ZA200102727B (en) | Method of treating sickle cell disease or thalassemia. | |
WO2003004046A3 (en) | Use of xaa-pro peptidases for the treatment of substance p-related disorders | |
AU2003223528A8 (en) | Treatment for type 1 diabetes before and after expression of predisposition markers. | |
NO20024545L (no) | Fremgangsmåte for behandling av kongestiv hjertefeil | |
WO2005110059A3 (en) | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |